Nervous System News and Research

Latest Nervous System News and Research

Avanir seeks EMA marketing authorization for NUEDEXTA to treat pseudobulbar affect

Avanir Pharmaceuticals, Inc. announced today that it has submitted an application to the European Medicines Agency seeking marketing authorization for NUEDEXTA (dextromethorphan HBr and quinidine sulfate) for the treatment of pseudobulbar affect.

31 Oct 2011

Mayo Clinic, Oxford BioMedica collaborate to develop gene therapy for glaucoma

Oxford BioMedica plc, the leading gene-based biopharmaceutical company, today announces that it has entered into a research and development collaboration with Mayo Clinic, Rochester (USA) to develop a novel gene therapy for the treatment of chronic glaucoma.

31 Oct 2011

Spinal cord meninges is a potential source of self-renewing stem cells

Italian and Spanish scientists studying the use of stem cells for treating spinal cord injuries have provided the first evidence to show that meninges, the membrane which envelops the central nervous system, is a potential source of self-renewing stem cells.

28 Oct 2011

Beneficial intestinal bacteria can activate immune cells and trigger MS

Multiple sclerosis is caused by a combination of genetic and environmental factors. For a long time, pathogens were believed to be such external influences. According to scientists from the Max Planck Institute of Neurobiology in Martinsried, however, it is apparently not harmful bacteria that trigger multiple sclerosis, but beneficial ones - specifically, the natural intestinal flora, which every human being needs for digestion.

28 Oct 2011

U of A researchers discover potential new drug target for MS

Medical researchers at the University of Alberta have discovered a potential new drug target for Multiple Sclerosis that could prevent physical disability associated with the disease, once a new drug is developed.

27 Oct 2011

Medtronic initiates Symplicity System clinical study in treatment-resistant hypertension

Medtronic Inc. announced today the start of SYMPLICITY HTN-3, the company's U.S. clinical trial of the Symplicity Renal Denervation System for treatment-resistant hypertension.

From Medtronic 27 Oct 2011

UCB, Emerald BioStructures extend structure-based drug discovery collaboration

Emerald BioStructures today announced a three-year extension of its ongoing collaboration with UCB. The strategic aspects of this renewed relationship will provide Emerald with research funding over the three-year period and the opportunity to receive milestones and royalties on future drug product revenues.

27 Oct 2011

FDA approves intraspinal injections in spinal cord stem cell ALS trial

Neuralstem, Inc. updated the progress of its ongoing Phase I safety trial of the company's spinal cord stem cells in the treatment of amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease) at Emory University in Atlanta, Georgia.

24 Oct 2011

Lundbeck's ONFI receives FDA approval for treating seizures associated with Lennox-Gastaut syndrome

Lundbeck Inc., a wholly owned subsidiary of H. Lundbeck A/S in Denmark, announced today that the U.S. Food and Drug Administration (FDA) has approved ONFI as adjunctive therapy for seizures associated with Lennox-Gastaut syndrome in patients two years and older.

24 Oct 2011

CoreLab Partners releases new semi-automated CalECG v3 solution

CoreLab Partners, Inc. has launched a new semi-automated ECG solution through its ongoing collaboration with Analyzing Medical Parameters for Solutions (A.M.P.S.) LLC.

24 Oct 2011

FDA accepts Ironwood and Forest Laboratories' linaclotide NDA for review

Ironwood Pharmaceuticals, Inc. and Forest Laboratories, Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for linaclotide for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic constipation.

24 Oct 2011

SCI patients with autonomic dysfunction more likely to develop heart disease

New research from the Heart and Stroke Foundation and the Christopher and Dana Reeve Foundation may help explain why people with spinal cord injury (SCI) have a higher risk of developing heart disease.

24 Oct 2011

Positive top line results from Shire's LDX phase III study on ADHD

Shire plc, the global specialty biopharmaceutical company, today presented positive top line results of the first European phase III study of once-daily lisdexamfetamine dimesylate (LDX) in children and adolescents aged 6 to 17 years with Attention-Deficit/Hyperactivity Disorder.

22 Oct 2011

Romark announces results from NT-300 Phase 2B-3 trial on influenza

Romark Laboratories announced that results of a large Phase 2B-3 US clinical trial of its new flu drug, NT-300 (nitazoxanide), will be presented as an oral late-breaking communication at the 49th Annual Meeting of the Infectious Diseases Society of America (IDSA) being held in Boston, October 20-23, 2011.

22 Oct 2011

Genentech announces 96-week results from ocrelizumab Phase II study on RRMS

Genentech, a member of the Roche Group, today announced 96-week results from a Phase II study of ocrelizumab in patients with relapsing-remitting multiple sclerosis (RRMS), the most common clinical form of the disease.

21 Oct 2011

Preclinical data from Teva's COPAXONE study on multiple sclerosis

Teva Pharmaceutical Industries Ltd. today announced preclinical data demonstrating reparative and neuroprotective effects of treatment with COPAXONE (glatiramer acetate injection) in experimental autoimmune encephalomyelitis (EAE) models.

21 Oct 2011

Tamandare Explorations is now Tonix Pharmaceuticals

Tonix Pharmaceuticals Holding Corp., a specialty pharmaceutical company developing therapies for challenging disorders of the central nervous system ("CNS"), including fibromyalgia syndrome ("FM") and post-traumatic stress disorder ("PTSD"), has announced the effectiveness of a company name change to Tonix Pharmaceuticals Holding Corp. and the commencement of trading under the stock symbol "TNXP".

20 Oct 2011

OPHN1 protein mediates mGluR-dependent longterm depression at synapses

Scientists at Cold Spring Harbor Laboratory (CSHL) have solved part of a puzzle concerning the relationship between changes in the strength of synapses - the tiny gaps across which nerve cells in the brain communicate - and dysfunctions in neural circuits that have been linked with drug addiction, mental retardation and other cognitive disorders.

20 Oct 2011

JHU, Eisai enter drug-discovery research collaboration for brain disorders

The Johns Hopkins University (JHU) has entered into a drug-discovery research collaboration with Eisai, a pharmaceutical company based in Tokyo, to develop proprietary small-molecule drugs for a range of brain conditions such as schizophrenia, pain, brain tumors and Alzheimer's disease.

20 Oct 2011

AAN updated guideline on how to best treat essential tremor

The American Academy of Neurology is releasing an updated guideline on how to best treat essential tremor, which is the most common type of tremor disorder and is often confused with other movement disorders such as Parkinson's disease.

20 Oct 2011